Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)

mAbs

Volumn 7, Issue 5, 2015, Pages 805-811

  Tebbey, Paul W ^a   Varga, Amy ^a   Naill, Michael ^a   Clewell, Jerry ^a   Venema, Jaap ^a  

^a ABBVIE INC   (United States)

Author keywords

Adalimumab; Biosimilars; Manufacturing; Oligosaccharides; Quality attributes

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN G; MANNOSE OLIGOSACCHARIDE; TETRAMETHYLBENZIDINE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; PRESCRIPTION DRUG;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG DETERMINATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PURITY; DRUG QUALITY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FLUORESCENCE ANALYSIS; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC50; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN STRUCTURE; STANDARDIZATION; STRUCTURE ANALYSIS; ANTIBODY AFFINITY; CHEMISTRY; DRUG STORAGE; QUALITY CONTROL; STANDARDS; SYNTHESIS;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIBODY AFFINITY; ANTIRHEUMATIC AGENTS; DRUG STABILITY; DRUG STORAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PRESCRIPTION DRUGS; QUALITY CONTROL;

EID: 84954309076     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1073429     Document Type: Article

References (25)

1. Abbvie Inc. Humira® [package insert]. North Chicago, IL: 2014.
2. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72:517-24; PMID:22562972; http://dx. doi. org/10. 1136/annrheumdis-2011-201244
3. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66:241-51; PMID:21752491; http:// dx. doi. org/10. 1016/j. jaad. 2010. 12. 005
4. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, Mozaffarian N. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013; 40:1487-97; PMID:23818718; http://dx. doi. org/ 10. 3899/jrheum. 120964
5. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-2; PMID:21478841; http://dx. doi. org/ 10. 1038/nbt. 1839
6. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72:315-8; PMID:23390018; http://dx. doi. org/10. 1136/annrheu mdis-2012-202941
7. European Medicines Agency. 2014. Humira procedural steps taken and scientific information after authorization. Available from: http://www. ema. europa. eu (accessed 15 September 2014)
8. International Conference on Harmonisation Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biologics Products; 1999 (Federal Register 64:44928)
9. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011; 365:385-8; PMID:21812668; http://dx. doi. org/10. 1056/NEJMp1107285
10. Abes R, Teillaud J. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 2010; 3:146-57; http://dx. doi. org/10. 3390/ph3010146
11. Antes B, Amon S, Rizzi A, Wiederkum S, Kainer M, Szolar O, Fido M, Kircheis R, Nechansky A. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 852:250-6; PMID:17296336; http://dx. doi. org/ 10. 1016/j. jchromb. 2007. 01. 024
12. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010; 30 Suppl 1:S9-14; PMID:20480216; http://dx. doi. org/10. 1007/s10875-010-9405-6
13. Bohm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Sem Immunopathol 2012; 34:443-53; http://dx. doi. org/10. 1007/s00281-012-0308-x
14. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22:1383-91; PMID:15529163; http://dx. doi. org/10. 1038/nbt1030
15. Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol 2011; 780:113-24; PMID:21842369; http://dx. doi. org/ 10. 1007/978-1-4419-5632-3_10
16. Dick LW, Jr., Kim C, Qiu D, Cheng KC. Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol Bioeng 2007; 97:544-53; PMID:17099914; http:// dx. doi. org/10. 1002/bit. 21260
17. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2010; 2:613-24; PMID:20818176; http://dx. doi. org/10. 4161/mabs. 2. 6. 13333
18. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-11; PMID:21283105; http://dx. doi. org/10. 1038/nrd3365
19. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-13; PMID:17727329; http://dx. doi. org/10. 1517/ 14712598. 7. 9. 1401
20. Lee S, Raw A, Yu L, Lionberger R, Ya N, Verthelyi D, Rosenberg A, Kozlowski S, Webber K, Woodcock J. Scientific considerations in the review and approval of generic enoxaparin in the United States. Nat Biotechnol 2013; 31:220-6; PMID:23471071; http:// dx. doi. org/10. 1038/nbt. 2528
21. Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. mAbs 2012; 4:385-91; PMID:22531450; http://dx. doi. org/10. 4161/mabs. 19868
22. Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. Increased serum clearance of oligomannose species present on a human IgG1 molecule. mAbs 2012; 4:509-20; PMID:22669558; http://dx. doi. org/ 10. 4161/mabs. 20450
23. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014; 343:1235681; PMID:24385630; http://dx. doi. org/ 10. 1126/science. 1235681
24. Ebbers HC, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, Schellekens H. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today 2013; 18:872-9; PMID:23688584; http://dx. doi. org/ 10. 1016/j. drudis. 2013. 05. 004
25. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx. doi. org/10. 1093/glycob/ cwr027